| Use of activated protein C in liver transplantation patients with septic shock. | |
| | |
MedLine Citation:
|
PMID: 18972572 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recombinant human activated protein C (rhAPC) has been approved for use in patients with severe sepsis at high risk of death. Because of the high risk of bleeding, liver transplantation (LT) patients have been excluded from the randomized control trials that evaluated efficacy and safety of rhAPC and, thus, few data are available on the use of this drug in LT patients with severe sepsis. We describe our experience with 5 LT recipients treated for septic shock with the best conventional therapy and rhAPC. Before rhAPC therapy, all the patients showed septic shock, with > or =3 organ dysfunctions and thrombocytopenia with impairment of coagulation. rhAPC therapy started within 30 hours after septic shock onset in all the patients who recovered from sepsis-induced circulatory failure, improved organ dysfunction, and completed the 96 hours of rhAPC therapy. During rhAPC infusion, 4 patients received fresh frozen plasma and/or platelet concentrates because of thrombocytopenia and severe hemostasis dysfunction. No major bleeding occurred and only 1 patient presented with minor bleeding events. |
| | |
Authors:
|
Laura Rinaldi; Marco Marietta; Mariano Alejandro Mignini; Lara Donno; Stefano Busani; Mauro Codeluppi; Michele Masetti; Massimo Girardis |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society Volume: 14 ISSN: 1527-6473 ISO Abbreviation: Liver Transpl. Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-11-04 Completed Date: 2009-04-27 Revised Date: 2009-12-02 |
Medline Journal Info:
|
Nlm Unique ID: 100909185 Medline TA: Liver Transpl Country: United States |
Other Details:
|
Languages: eng Pagination: 1598-602 Citation Subset: IM |
Affiliation:
|
Department of Anaesthesiology and Intensive Care Unit, University of Modena and Reggio Emilia, University Hospital of Modena [corrected] Eli-Lilly Italia, Sesto Fiorentino, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Aged Female Hemorrhage / drug therapy Humans Liver Transplantation / methods* Male Middle Aged Platelet Count Protein C / therapeutic use* Recombinant Proteins / therapeutic use Shock, Septic / therapy* Thrombocytopenia / etiology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Protein C; 0/Recombinant Proteins |
| Comments/Corrections | |
Comment In:
|
Liver Transpl. 2009 Dec;15(12):1901-2
[PMID:
19938105
]
|
Erratum In:
|
Liver Transpl. 2009 Jan;15(1):119 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cochlear implant use following neonatal deafness influences the cochleotopic organization of the pri...
Next Document: Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone.